PHILADELPHIA--(BUSINESS WIRE)--Hemispherx, Inc. (Amex: HEB), a biopharmaceutical firm focused on RNA-based therapeutic solutions for chronic severely debilitating diseases, has today commented on the growing visibility of Chronic Fatigue Syndrome (“CFS”) as a serious disease.
